Treatment continuation in patients receiving biological agents or conventional DMARD therapy.
about
Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databasesBiologics registers in RA: methodological aspects, current role and future applications.Health-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German biologics register RABBIT.Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project.Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT.The value of observational cohort studies for cancer drugs.74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis.Drug survival rates of tumor necrosis factor inhibitors in patients with rheumatoid arthritis and ankylosing spondylitis.A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registriesFcγ receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis.Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics RegisterMethotrexate in rheumatoid arthritis is frequently effective, even if re-employed after a previous failure.Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low--results from RABBIT, the German biologics register.Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab.Infliximab: 12 years of experienceFour-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity.Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern SwedenEvidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in GermanyBiologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany.The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era.Nucleosides accelerate inflammatory osteolysis, acting as distinct innate immune activators.Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2)Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug.Comparison of Biologic Disease-Modifying Antirheumatic Drug Therapy Persistence Between Biologics Among Rheumatoid Arthritis Patients Switching from Another Biologic.Use of Anti-Tumor Necrosis Factor Therapy: A Retrospective Study of Monotherapy and Adherence to Combination Therapy with Non-Biologic Disease-Modifying Anti-Rheumatic Drugs.Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritis.Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan.Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and with disability.Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis.Long-Term Drug Survival of TNF Inhibitor Therapy in RA Patients: A Systematic Review of European National Drug Registers.New and emerging therapies for the treatment of rheumatoid arthritis.Reappraisal of the clinical use of leflunomide in rheumatoid arthritis and psoriatic arthritis.Comparative effectiveness of infliximab and adalimumab for Crohn's disease.Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany.Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy.Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study.Adherence to biologic DMARD therapies in rheumatoid arthritis.Rheumatoid arthritis and the era of biologic therapy.Economics of non-adherence to biologic therapies in rheumatoid arthritis.
P2860
Q26778600-3D3C1AC5-0A62-495A-9871-08BC764E98EFQ30234303-C735992D-D4D2-48AC-B7D1-8563B2037CC4Q30957102-DCEE97EE-FC1D-4BE8-AA10-BD9510C48C24Q33573112-D5F75ECF-3A91-4733-B5A9-9B62B950723AQ33873620-411B2C0B-0420-4797-90E9-D3DFBD2E4456Q33973945-96CD534D-B376-48F3-8BE8-9549955D5364Q34027648-7841C3AD-2F0F-4849-82FC-535E27612110Q34208252-B2A1456A-D586-41CC-8E44-EE05A9DCDC15Q34216770-22947A2E-A737-474B-981D-C4C874652362Q34462584-58263849-5086-4B50-A941-DDD61A3D0474Q34623922-C59818DA-E0AF-4053-9C82-AA64C5778E11Q34896997-35152730-D9C4-490D-9DD0-F48777491BA6Q34897423-68276727-DD7F-473C-B951-49CD6DF000D4Q35048347-3AE9F0FC-1672-4F8B-AD2C-7FB82AE4D9A0Q35070446-2693DD03-1A38-4AE2-8DAB-07645210205EQ35605643-39BC39C7-4B48-4518-B2B1-42264BD4FCBAQ35630063-B3FFDDFD-5C8B-434D-91CD-675683492FF6Q35637221-2FC6AB90-34D3-4A7A-BDC6-12E874FB45DAQ35637894-2D58C64B-7D0E-44C9-B635-154FC9BC12A0Q35851000-5F30ECDD-E380-4EE9-B553-93D36DD3871AQ36064093-5AF20CA8-070F-48EC-9516-36BB5916D5FAQ36257329-6C7B6D81-F654-4DFA-899F-0F541CEB50D2Q36517701-2BDDD2E9-F1EF-41E6-A40E-FA539346D922Q36725347-DFD2369B-EE60-4D1E-9B29-B7DBDAD603AAQ36942952-207505B0-58C6-4A66-A57D-9E95238C4F72Q36943002-E7738A4B-85BF-4EA5-B3A8-E02F866957B1Q37156561-8290A286-FCF7-476D-887B-82F0E904F367Q37167818-B68C27D0-32C1-4113-BB35-82E43EEB44B0Q37207129-EFFF352F-136F-45C8-9120-22C343A3AD07Q37235732-790DF7D6-3167-48AE-88A1-FBEE3411C607Q37338261-0E732200-D60E-4123-8089-5364C55EB5A0Q37358229-0E0A50C8-B9BF-41AA-BD05-84A31176FD95Q37358239-043C7536-CAEA-4818-8792-298CDE5EDFE8Q37445629-A2C83B86-B98D-4BF4-8D87-85A5480FB1B7Q37452672-293B04EA-C80A-4F08-8894-31016C241DD6Q37473766-288CAD36-9F59-4F2B-BB92-B039A9466BD3Q37715956-6D248512-14F1-4030-B8F6-8100E732A040Q37777418-6EB3D6AD-5A67-48D3-9D81-76B49B34B34AQ37988317-D2C30BDB-63A8-4BCC-B488-BD24BBB5876DQ38250160-700BDD16-4416-4FC9-BBC0-BA8A95BAF24D
P2860
Treatment continuation in patients receiving biological agents or conventional DMARD therapy.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Treatment continuation in pati ...... or conventional DMARD therapy.
@ast
Treatment continuation in pati ...... or conventional DMARD therapy.
@en
type
label
Treatment continuation in pati ...... or conventional DMARD therapy.
@ast
Treatment continuation in pati ...... or conventional DMARD therapy.
@en
prefLabel
Treatment continuation in pati ...... or conventional DMARD therapy.
@ast
Treatment continuation in pati ...... or conventional DMARD therapy.
@en
P2093
P2860
P356
P1476
Treatment continuation in pati ...... or conventional DMARD therapy.
@en
P2093
Babinsky K
Gromnica-Ihle E
Schneider M
P2860
P304
P356
10.1136/ARD.2004.031476
P407
P577
2005-02-11T00:00:00Z